JP MORGAN/PUT/VERTEX PHARMACEUTICALS/370/0.1/17.01.25 | Market Closed - Bid/Ask 02:49:52 28/06/2024 pm IST | Pre-market 11:30:15 am | |||
| 0.63 EUR | +3.28% |
|
0.91 | +44.44% |
| Current month | -50.00% | ||
| 1 month | -33.68% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 0.63 | +3.28% |
| 27/24/27 | 0.61 | -1.61% |
| 25/24/25 | 0.62 | -13.89% |
| 24/24/24 | 0.72 | +1.41% |
| 21/24/21 | 0.71 | -11.25% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 02:49 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB3R7D |
| ISIN | DE000JB3R7D0 |
| Date issued | 13/10/2023 |
| Strike | 370 $ |
| Maturity | 17/01/2025 (201 Days) |
| Parity | 10 : 1 |
| Emission price | 3.62 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.1 € |
|---|---|
| Lowest since issue | 0.61 € |
| Spread | 0.3 € |
| Spread % | 30.93% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Warrants
- Warrant
